Members Only Content

Subscribe to get full access

Free Preview

On 27th April, Teladoc issued disappointing Q1 2022 results leading to a 40% one-day drop in valuation. Although customer and revenue growth was broadly in-line with forecasts, company leadership highlighted the growing competition from well capitalised health-tech startups, resulting in increased costs for paid search and a lower than expected return on marketing spend. These are clear signs that Telemedicine is becoming a commoditised sector, and thus far Teladoc has not demonstrated that it has a differentiated service. This presents the concern that the company may not have pricing power, potentially constraining revenue growth in the future.

related news & insights

  • May 16, 2025||46.1 min||||

    What’s Next for Digital Advertising? 7investing Interviews PubMatic CEO Rajeev Goel

    PubMatic just reported first quarter 2025 results. Aside from the headwinds of a DSP partner changing its bidding process, the [...]

  • May 14, 2025||2.6 min||||

    7investing Exclusive: A Deep Dive Into Rocket Lab

    The space economy is hitting an inflection point. And that will be good news for its earliest investors. Eastern European [...]

  • May 8, 2025||0 min||||

    DraftKings Deep Dive: May 2025

    DraftKings Recommendation Report